EGFR and non-small cell lung carcinoma: Although ALYREF has not been specifically reported regarding chemotherapeutic drug resistance, Wang et al. found that NSUN2 modulated gefitinib resistance in EGFR-mutated non-small cell lung cancers, and Chen et al. demonstrated that NSUN2 functions as a glucose sensor to maintain tumorigenicity and confer immunotherapeutic resistance [38, 39].